A non-hallucinogenic psychedelic analogue with therapeutic potential.
Cameron LP, Tombari RJ, Lu J, Pell AJ, Hurley ZQ, Ehinger Y, Vargas MV, McCarroll MN, Taylor JC, Myers-Turnbull D, Liu T, Yaghoobi B, Laskowski LJ, Anderson EI, Zhang G, Viswanathan J, Brown BM, Tjia M, Dunlap LE, Rabow ZT, Fiehn O, Wulff H, McCorvy JD, Lein PJ, Kokel D, Ron D, Peters J, Zuo Y, Olson DE.
Nature. 2021 Jan;589(7842):474-479. doi: 10.1038/s41586-020-3008-z. Epub 2020 Dec 9.
Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation.
McLellan AT, Lewis DC, O'Brien CP, Kleber HD.
JAMA. 2000 Oct 4;284(13):1689-95. doi: 10.1001/jama.284.13.1689.
Opioid receptors.
Waldhoer M, Bartlett SE, Whistler JL.
Annu Rev Biochem. 2004;73:953-90. doi: 10.1146/annurev.biochem.73.011303.073940.
Nalbuphine.
Schmidt WK, Tam SW, Shotzberger GS, Smith DH Jr, Clark R, Vernier VG.
Drug Alcohol Depend. 1985 Feb;14(3-4):339-62. doi: 10.1016/0376-8716(85)90066-3.
Current benzodiazepine issues.
Woods JH, Winger G.
Psychopharmacology (Berl). 1995 Mar;118(2):107-15; discussion 118, 120-1. doi: 10.1007/BF02245824.
Ketamine dependence.
Pal HR, Berry N, Kumar R, Ray R.
Anaesth Intensive Care. 2002 Jun;30(3):382-4. doi: 10.1177/0310057X0203000323.
Pharmacokinetic determinants of drug abuse and dependence. A conceptual perspective.
Busto U, Sellers EM.
Clin Pharmacokinet. 1986 Mar-Apr;11(2):144-53. doi: 10.2165/00003088-198611020-00004.
Antismoking products.
Gourlay SG, McNeil JJ.
Med J Aust. 1990 Dec 3-17;153(11-12):699-707. doi: 10.5694/j.1326-5377.1990.tb126327.x.
Addiction to benzodiazepines.
Salzman C.
Psychiatr Q. 1998 Winter;69(4):251-61. doi: 10.1023/a:1022125929946.
Abuse potential of non-nicotine tobacco smoke components: acetaldehyde, nornicotine, cotinine, and anabasine.
Hoffman AC, Evans SE.
Nicotine Tob Res. 2013 Mar;15(3):622-32. doi: 10.1093/ntr/nts192. Epub 2012 Sep 18.
